Drugs / Live attenuated H7N9 A/Anhui/13 ca influenza virus vaccine
Live attenuated H7N9 A/Anhui/13 ca influenza virus vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01995695 | Oct 2013 → Jan 2016 | swine influenza | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Live attenuated H7N9 A/Anhui/13 ca influenza virus vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01995695 ↗ |
| Modality | Vaccine | “The purpose of this study is to evaluate the safety and immunogenicity of a live attenuated H7N9 A/Anhui/13 ca influenza virus vaccine in healthy adults.” NCT01995695 ↗ |
| Route | Intranasal | “The vaccine will be delivered by an Accuspray nasal spray device” NCT01995695 ↗ |